Preliminary results of pravastatin on non-hemorrhagic vertebral artery dissection: an exploratory randomized and controlled study
Abstract Background There is limited information about the pleiotropic effects of statin on cerebrovascular diseases. The authors aimed to investigate the effect of pravastatin on non-hemorrhagic vertebral artery dissection (VAD) in a clinical setting. Methods An exploratory randomized and controlle...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | BMC Neurology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12883-025-04257-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850137984215547904 |
|---|---|
| author | Hyun Jin Han Keun Young Park Chang Ki Jang Joonho Chung Yong Bae Kim Sung Ho Lee Kangmin Kim Hyun-Seung Kang Jeong Eun Kim Won-Sang Cho |
| author_facet | Hyun Jin Han Keun Young Park Chang Ki Jang Joonho Chung Yong Bae Kim Sung Ho Lee Kangmin Kim Hyun-Seung Kang Jeong Eun Kim Won-Sang Cho |
| author_sort | Hyun Jin Han |
| collection | DOAJ |
| description | Abstract Background There is limited information about the pleiotropic effects of statin on cerebrovascular diseases. The authors aimed to investigate the effect of pravastatin on non-hemorrhagic vertebral artery dissection (VAD) in a clinical setting. Methods An exploratory randomized and controlled study was designed for the non-hemorrhage VAD (CRIS, KCT00035970). Primary outcomes were 1- and 6-month radiologic changes on vessel wall magnetic resonance imaging (VW-MRI), with secondary outcomes related to the clinical and laboratory parameters, and safety outcomes of the pravastatin use. Results Finally, 23 patients were enrolled, consisting of 12 in the pravastatin group and 11 in the control with similar baseline characteristics except the age (55.0 versus 45.5 years, P = .01). Morphologic changes in the early period (0–1 month) were more improved or resolved in the pravastatin group with a borderline significance (crude odds ratio: 7.500 [95% confidence interval: 0.921-64.047], P = .06). However, age-adjusted analysis showed no difference in morphologic changes between the groups (adjusted odds ratio: 0.853 [95% confidence interval: 0.033-22.020], P = .92). The serum level of high-sensitivity C-reactive protein (hs-CRP) in the pravastatin group showed a descending tendency in the early period (Z-score: -1.843, P = .07), whereas it significantly increased in the control (Z-score: -2.371, P = .02). There were no safety issues at all. Conclusion Pravastatin had a borderline significant effect on the recovery of non-hemorrhage VAD with no additional adverse effects. A further study with a larger scale is expected to make more concrete evidences about the pleiotropic effects of statin on the non-hemorrhagic VAD. Trial registration The present study registered in a clinical research information service approved by World Health Organization (CRIS, KCT00035970, Registered on 7 March 2019; available at: https://cris.nih.go.kr/cris/search/detailSearch.do?seq=25234%26status=5%26seq_group=12949%26search_page=M ). |
| format | Article |
| id | doaj-art-3436706abd8e46f5bbf30eaddf79b4b0 |
| institution | OA Journals |
| issn | 1471-2377 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Neurology |
| spelling | doaj-art-3436706abd8e46f5bbf30eaddf79b4b02025-08-20T02:30:42ZengBMCBMC Neurology1471-23772025-06-012511910.1186/s12883-025-04257-7Preliminary results of pravastatin on non-hemorrhagic vertebral artery dissection: an exploratory randomized and controlled studyHyun Jin Han0Keun Young Park1Chang Ki Jang2Joonho Chung3Yong Bae Kim4Sung Ho Lee5Kangmin Kim6Hyun-Seung Kang7Jeong Eun Kim8Won-Sang Cho9Departments of Neurosurgery, Severance HospitalDepartments of Neurosurgery, Severance HospitalYongin Severance HospitalGangnam Severance HospitalDepartments of Neurosurgery, Severance HospitalDepartment of Neurosurgery, Seoul National University Hospital, Seoul National University College of MedicineDepartment of Neurosurgery, Seoul National University Hospital, Seoul National University College of MedicineDepartment of Neurosurgery, Seoul National University Hospital, Seoul National University College of MedicineDepartment of Neurosurgery, Seoul National University Hospital, Seoul National University College of MedicineDepartment of Neurosurgery, Seoul National University Hospital, Seoul National University College of MedicineAbstract Background There is limited information about the pleiotropic effects of statin on cerebrovascular diseases. The authors aimed to investigate the effect of pravastatin on non-hemorrhagic vertebral artery dissection (VAD) in a clinical setting. Methods An exploratory randomized and controlled study was designed for the non-hemorrhage VAD (CRIS, KCT00035970). Primary outcomes were 1- and 6-month radiologic changes on vessel wall magnetic resonance imaging (VW-MRI), with secondary outcomes related to the clinical and laboratory parameters, and safety outcomes of the pravastatin use. Results Finally, 23 patients were enrolled, consisting of 12 in the pravastatin group and 11 in the control with similar baseline characteristics except the age (55.0 versus 45.5 years, P = .01). Morphologic changes in the early period (0–1 month) were more improved or resolved in the pravastatin group with a borderline significance (crude odds ratio: 7.500 [95% confidence interval: 0.921-64.047], P = .06). However, age-adjusted analysis showed no difference in morphologic changes between the groups (adjusted odds ratio: 0.853 [95% confidence interval: 0.033-22.020], P = .92). The serum level of high-sensitivity C-reactive protein (hs-CRP) in the pravastatin group showed a descending tendency in the early period (Z-score: -1.843, P = .07), whereas it significantly increased in the control (Z-score: -2.371, P = .02). There were no safety issues at all. Conclusion Pravastatin had a borderline significant effect on the recovery of non-hemorrhage VAD with no additional adverse effects. A further study with a larger scale is expected to make more concrete evidences about the pleiotropic effects of statin on the non-hemorrhagic VAD. Trial registration The present study registered in a clinical research information service approved by World Health Organization (CRIS, KCT00035970, Registered on 7 March 2019; available at: https://cris.nih.go.kr/cris/search/detailSearch.do?seq=25234%26status=5%26seq_group=12949%26search_page=M ).https://doi.org/10.1186/s12883-025-04257-7PravastatinPleiotropic effectsVertebral artery dissectionMagnetic resonance imagingPilot study |
| spellingShingle | Hyun Jin Han Keun Young Park Chang Ki Jang Joonho Chung Yong Bae Kim Sung Ho Lee Kangmin Kim Hyun-Seung Kang Jeong Eun Kim Won-Sang Cho Preliminary results of pravastatin on non-hemorrhagic vertebral artery dissection: an exploratory randomized and controlled study BMC Neurology Pravastatin Pleiotropic effects Vertebral artery dissection Magnetic resonance imaging Pilot study |
| title | Preliminary results of pravastatin on non-hemorrhagic vertebral artery dissection: an exploratory randomized and controlled study |
| title_full | Preliminary results of pravastatin on non-hemorrhagic vertebral artery dissection: an exploratory randomized and controlled study |
| title_fullStr | Preliminary results of pravastatin on non-hemorrhagic vertebral artery dissection: an exploratory randomized and controlled study |
| title_full_unstemmed | Preliminary results of pravastatin on non-hemorrhagic vertebral artery dissection: an exploratory randomized and controlled study |
| title_short | Preliminary results of pravastatin on non-hemorrhagic vertebral artery dissection: an exploratory randomized and controlled study |
| title_sort | preliminary results of pravastatin on non hemorrhagic vertebral artery dissection an exploratory randomized and controlled study |
| topic | Pravastatin Pleiotropic effects Vertebral artery dissection Magnetic resonance imaging Pilot study |
| url | https://doi.org/10.1186/s12883-025-04257-7 |
| work_keys_str_mv | AT hyunjinhan preliminaryresultsofpravastatinonnonhemorrhagicvertebralarterydissectionanexploratoryrandomizedandcontrolledstudy AT keunyoungpark preliminaryresultsofpravastatinonnonhemorrhagicvertebralarterydissectionanexploratoryrandomizedandcontrolledstudy AT changkijang preliminaryresultsofpravastatinonnonhemorrhagicvertebralarterydissectionanexploratoryrandomizedandcontrolledstudy AT joonhochung preliminaryresultsofpravastatinonnonhemorrhagicvertebralarterydissectionanexploratoryrandomizedandcontrolledstudy AT yongbaekim preliminaryresultsofpravastatinonnonhemorrhagicvertebralarterydissectionanexploratoryrandomizedandcontrolledstudy AT sungholee preliminaryresultsofpravastatinonnonhemorrhagicvertebralarterydissectionanexploratoryrandomizedandcontrolledstudy AT kangminkim preliminaryresultsofpravastatinonnonhemorrhagicvertebralarterydissectionanexploratoryrandomizedandcontrolledstudy AT hyunseungkang preliminaryresultsofpravastatinonnonhemorrhagicvertebralarterydissectionanexploratoryrandomizedandcontrolledstudy AT jeongeunkim preliminaryresultsofpravastatinonnonhemorrhagicvertebralarterydissectionanexploratoryrandomizedandcontrolledstudy AT wonsangcho preliminaryresultsofpravastatinonnonhemorrhagicvertebralarterydissectionanexploratoryrandomizedandcontrolledstudy |